MTOR and hepatocellular carcinoma: The PI3K/AKT/mTOR pathway is also activated in some HCCs by mutations in different genes from the pathway or upstream effectors, and alterations in this pathway have been linked to resistance to sorafenib [75,76], the most used systemic drug against HCC.